Citations

Clear

1325 citation(s) found for "Mayo, Angela".

GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression
Tolosa, Ezequiel J. , Iguchi, Eriko , McCleary‐Wheeler, Angela L. , Carr, Ryan M. , Almada, Luciana L. , Flores, Luis F. , Vera, Renzo E., Alfonse, Germine W., Marks, David L. , Hogenson, Tara L. , Vrabel, Anne M., Horn, Isaac P. , Koenig, Amanda, Safgren, Stephanie L. , Sigafoos, Ashley N. , Erkan, Mert , Romecín, Paola , Gonzalez, Alejandro Sarabia, Javelaud, Delphine , Marsaud, Véronique, Graham, Rondell P. , Elsawa, Sherine F. , Fernández-Zapico, Martín E. , Fernandez-Barrena, Maite G, McCleary-Wheeler, Angela L, Koenig, Amanda N, Romecin-Duran, Paola A, Sarabia Gonzalez, Alejandro, Elsawa, Sherine F , Graham, Rondell P , Safgren, Stephanie L , Carr, Ryan M , Fernández‐Barrena, Maite G. , Zhou, Bo , Mauviel, Alain

Mayo Clinic

Biochemical Journal | August 7, 2020 | Volume: 477 | Issue: 17 | Pages: 3131-3145

10.1042/bcj20200335 | PMID 32766732 Get It

The Hedgehog-regulated transcription factors GLI1 and GLI2 play overlapping roles in development and disease; however, the mechanisms underlying their interplay remain elusive. We report for the first time that GLI1 and GLI2 physically and functionally interact in cancer cells. GLI1 and GLI2 were shown to co-immunoprecipitate in PANC1 pancreatic cancer cells and RMS13 rhabdomyosarcoma cells. Mapping analysis demonstrated that the zinc finger domains of both proteins are required for their heteromerization. RNAi knockdown of either GLI1 or GLI2 inhibited expression of many well-characterized GLI target genes (BCL2, MYCN, PTCH2, IL7 and CCND1) in PANC1 cells, whereas PTCH1 expression was only inhibited by GLI1 depletion. qPCR screening of a large set of putative canonical and non-canonical Hedgehog/GLI targets identified further genes (e.g. E2F1, BMP1, CDK2) strongly down-regulated by GLI1 and/or GLI2 depletion in PANC1 cells, and demonstrated that ANO1, AQP1 and SOCS1 are up-regulated by knockdown of either GLI1 or GLI2. Chromatin immunoprecipitation showed that GLI1 and GLI2 occupied the same regions at the BCL2, MYCN and CCND1 promoters. Furthermore, depletion of GLI1 inhibited GLI2 occupancy at these promoters, suggesting that GLI1/GLI2 interaction is required for the recruitment of GLI2 to these sites. Together, these findings indicate that GLI1 and GLI2 co-ordinately regulate the transcription of some genes, and provide mechanistic insight into the roles of GLI proteins in carcinogenesis.
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Abdallah, Nadine , Greipp, Patricia T. , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Buadi, Francis K. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Siddiqui, Mustaqeem , Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Gertz, Morie A , Buadi, Francis K , Siddiqui, Mustaqeem A , Dingli, David , Greipp, Patricia T , Lin, Yi , Dispenzieri, Angela , Baughn, Linda B. , Go, Ronald S. , Leung, Nelson , Ketterling, Rhett P. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | August 4, 2020 | Volume: 4 | Issue: 15 | Pages: 3509-3519

10.1182/bloodadvances.2020002218 | PMID 32750129 Get It

Abstract A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)–, immunomodulatory drug (iMiD)–, or PI plus IMiD–based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P < .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P < .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age ≥70 years were included (RR, 1.5; P < .001). Gain of >1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio
Muchtar, Eli , Gertz, Morie A. , Lacy, Martha Q. , Leung, Nelson , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Russell, Stephen J. , Lust, John A., Siddiqui, Mustaqeem , Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi Lisa, Russell, Stephen, Rajkumar, S Vincent , Dispenzieri, Angela , Gertz, Morie A , Leung, Nelson , Muchtar, E , Russell, Stephen J , Siddiqui, Mustaqeem A , Dingli, David , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 18, 2020 | Volume: 95 | Issue: 11 | Pages: 1280-1287

10.1002/ajh.25940 | PMID 32681737 Get It

AbstractResponse assessment in light chain (AL) amyloidosis is based on serum and urine monoclonal protein studies. Newly diagnosed patients (n = 373) who achieved very good partial response or complete response (CR) to first line therapy were assessed for the survival impact of each of the monoclonal protein studies. At end of therapy (EOT), negative serum/urine immunofixation (IFE) was achieved in 61% of patients, 72% achieved normal serum free light chain ratio (sFLCR), and the median involved free light chain (iFLC) and difference between involved to uninvolved light chain (dFLC) were 17 mg/L and 5 mg/L, respectively. Overall, 46% of patients achieved a CR at EOT. At EOT, iFLC ≤20 mg/L and dFLC ≤10 mg/L were additive in survival discrimination to negative serum/urine IFE and were independent predictors of overall survival. In contrast, normalization of sFLCR did not add survival discrimination to serum/urine IFE and was not independent predictor of survival. We propose a new definition for hematological CR to include serum/urine IFE negativity plus iFLC ≤20 mg/L or dFLC ≤10 mg/L, instead of the current definition of serum/urine IFE negativity and normal sFLCR. Complete response using dFLC ≤10 mg/L had the best performance in those with significant renal dysfunction and by light chain isotype, making it the preferred partner to IFE. Validation of these results in a multicenter cohort is warranted.
Intranasal Corticosteroid Therapy: Systematic Review and Meta‐analysis of Reported Safety and Adverse Effects in Children
Donaldson, Angela M. , Marks, Lisa A., Choby, Garret , Kim, Daniel Hyeong Seok , Marks, Lisa , Lal, Devyani

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 14, 2020 | Volume: 163 | Issue: 6 | Pages: 1087-1096

10.1177/0194599820931454 | PMID 32660332 Get It

Objectives To address concerns related to the safety profile of both Food and Drug Administration (FDA)–approved and non‐FDA‐approved intranasal corticosteroid (INCS) use in the pediatric population. Data Source Systematic review of MEDLINE, PubMed, and EMBASE databases using comprehensive search strategy, including all INCS formulations and adverse events. The study design was developed using Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Additional sources were identified from study references of relevant articles. Review Methods A structured literature search was conducted. Extracted data included age, population size, study design, drug (dosage, route, and frequency), presence of hypothalamic‐pituitary‐adrenal (HPA) axis suppression, ocular symptoms, and growth velocity adverse events. Results A total of 33 studies met inclusion criteria. The studies included use of INCS as nasal sprays and drops. There were no persistent abnormalities noted in cortisol level or intraocular pressure change. Growth velocity reduction was reported in 3 of 10 randomized trials. Meta‐analysis of epistaxis and headache showed no significant difference in the incidence of headache or epistaxis when FDA‐approved INCSs were compared to placebo, with a relative risk of 1.12 (95% CI, 0.77‐1.63; P =. 56) and 0.84 (95% CI, 0.60‐1.18; P =. 32), respectively. Meta‐analysis was not performed for growth velocity, HPA axis suppression, and ocular change. Conclusions INCSs in FDA‐approved routes of administration are generally safe to use in the pediatric population. Use of non‐FDA‐approved INCS drops may increase risk of iatrogenic Cushing’s syndrome. Growth velocity reduction, HPA axis suppression, and visual changes due to INCS are uncommon.
Systemic Amyloidosis Recognition, Prognosis, and Therapy
Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

JAMA | July 7, 2020 | Volume: 324 | Issue: 1 | Pages: 79

10.1001/jama.2020.5493 | PMID 32633805 Get It

Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
Heybeli, Cihan , Sridharan, Meera , Chen, Dong , Dingli, David , Gertz, Morie A. , Hashmi, Shahrukh K. , Hayman, Suzanne R. , Inwards, David J. , Kumar, Shaji , Litzow, Mark R. , Porrata, Luis F. , Lacy, Martha Q. , Micallef, Ivana N. , Patnaik, Mrinal M. , Villasboas Bisneto, Jose C, Chen, Dong , Dispenzieri, Angela , Gertz, Morie A , Kenderian, Saad Sirop , Litzow, Mark R. , Patnaik, Mrinal , Leung, Nelson , Dingli, David , Sridharan, Meera , Alkhateeb, Hassan B. , Villasboas, José C. , Buadi, Francis K. , Dispenzieri, Angela , Go, Ronald S. , Hogan, William J. , Kenderian, Saad S. , Shah, Meera , Leung, Nelson

Mayo Clinic

American Journal of Hematology | July 3, 2020 | Volume: 95 | Issue: 10 | Pages: 1170-1179

10.1002/ajh.25922 | PMID 32618000 Get It

AbstractTransplant‐associated thrombotic microangiopathy (TA‐TMA) has a wide range of presentations after hematopoietic stem‐cell transplantation (HSCT). We retrospectively studied the risk factors and outcomes of patients with early (≤day 100) and late (>day 100) TA‐TMA. Among the 1451 HSCT recipients, early TA‐TMA occurred in 45 (3.1%) patients at a median of 27 (3‐91) days, and late TA‐TMA in 39 (2.7%) patients at a median of 303 (122‐2595) days. Patients with early TA‐TMA were more likely to have high blood calcineurin‐inhibitor levels (P < .001) and acute graph‐vs‐host disease (GVHD, P < .001), while late TMA patients were more likely to have chronic GVHD (P < .001). The estimated median overall survival after onset of TMA for the entire cohort was 6 months. The estimated median overall survival was not reached in patients with an improvement of TMA vs 2 months in patients with no improvement (P < .001). In the early TMA group, older age (for every 10 years, HR 1.40; 95% CI 1.00‐1.94; P = .049) and bacterial infection (HR 2.42; 95% CI 0.98‐6.00; P = .056) were positively associated with mortality. Switching to MMF treatment (HR 0.40; 95% CI 0.16‐0.99; P = .047) and improvement of TMA (HR 0.08; 95% CI 0.03‐0.25; P < .001) were negatively associated with mortality in the multivariate analysis. In the late TMA group, the improvement of TMA was the only independent predictor associated with a lower risk of death (HR 0.05; 95% CI 0.02‐0.19; P < .001). Mortality rates in both early and late TMA remain unacceptably high. Future studies are needed for early diagnosis, trigger identifications, and use of targeted treatments.
Endoscopic endonasal odontoidectomy for the treatment of basilar invagination
Ruiz-García, Henry , Gassie, Kelly , Marenco-Hillembrand, Lina , Donaldson, Angela M. , Chaichana, Kaisorn L.

Mayo Clinic

Neurosurgical Focus: Video | July 1, 2020 | Volume: 3 | Issue: 1 | Pages: V3

10.3171/2020.3.focusvid.20184 | PMID 36285120 Get It

Basilar invagination is a challenging dilemma that neurosurgeons may face. Herein, we present a case of a 65-year-old female with a history of rheumatoid arthritis and status post a previous C4–7 ACDF who presented to our clinic with progressive weakness in her bilateral upper and lower extremities. Imaging revealed basilar invagination. She underwent an endoscopic endonasal odontoidectomy followed by an occiput–C6 fusion. We present the endonasal portion of the procedure and have highlighted the technical nuances of this approach. Our goal is to provide better insight into this surgical strategy when dealing with basilar invagination. The video can be found here: https://youtu.be/aeMbvI_zYQA
Free Light Chain Assay Drift: Potential for Misdiagnosis?
Murray, David , Kumar, Shaji , Gill, Hillary, Vachon, Celine M. , Snyder, Melissa R. , Vachon, Celine, Willrich, Maria, Dispenzieri, Angela , Gill, Hillary E, Vachon, Celine M. , Willrich, Maria Alice V.

Mayo Clinic

The Journal of Applied Laboratory Medicine | June 18, 2020 | Volume: 5 | Issue: 6 | Pages: 1411-1413

10.1093/jalm/jfaa093 | PMID 32829402 Get It